Loading clinical trials...
Loading clinical trials...
A Phase 1b/3, Multicenter, Trial of Talimogene Laherparepvec in Combination With Pembrolizumab (MK-3475) for Treatment of Unresectable Stage IIIB to IVM1c Melanoma (MASTERKEY-265)
Conditions
Interventions
Talimogene Laherparepvec
Pembrolizumab
+1 more
Locations
161
United States
Research Site
Birmingham, Alabama, United States
Research Site
Mobile, Alabama, United States
Research Site
Beverly Hills, California, United States
Research Site
Duarte, California, United States
Research Site
Encinitas, California, United States
Research Site
La Jolla, California, United States
Start Date
December 8, 2014
Primary Completion Date
March 11, 2021
Completion Date
March 11, 2021
Last Updated
November 14, 2022
NCT05969860
NCT03340506
NCT04693377
NCT05111574
NCT04895709
NCT06500455
Lead Sponsor
Amgen
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions